TL;DR
This study reveals that SPOCK1, a protein often overexpressed in breast cancer (BC), drives tumor progression by interacting with SIX1 and activating the AKT/mTOR signaling pathway. This interaction promotes cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT), suggesting SPOCK1 and SIX1 as potential therapeutic targets for BC.
What Problem Does This Paper Address?
Breast cancer (BC) remains a leading cause of cancer-related deaths, with metastasis being a primary driver of poor outcomes. While SPOCK1 is known to be upregulated in various cancers and associated with progression, its specific role and underlying mechanisms in breast cancer remain unclear. This research aims to elucidate how SPOCK1 contributes to BC progression, focusing on its involvement in cell proliferation and epithelial-mesenchymal transition (EMT), a key process in metastasis.
Methods
The researchers employed a multi-pronged approach:
- Database Analysis: They utilized public databases (Oncomine, UALCAN, HPA, TCGA, GEPIA2, Kaplan-Meier plotter, SurvExpress) to analyze SPOCK1 and SIX1 expression levels in various cancers, including BC, and their correlation with clinical parameters and patient prognosis.
- In Vitro Assays:
- Western Blotting: To assess protein expression levels of SPOCK1, SIX1, and key signaling pathway components (AKT, mTOR, etc.) in different BC cell lines and after genetic manipulation (knockdown/overexpression).
- Immunohistochemistry (IHC): To visualize SPOCK1 and SIX1 protein expression in BC tissue samples.
- Cell Proliferation Assays: MTT and EdU incorporation assays were used to measure cell growth and DNA synthesis.
- Colony Formation Assay: To evaluate the clonogenic capacity of BC cells.
- Flow Cytometry: To analyze cell cycle progression.
- Wound Healing Assay: To assess cell motility and migration.
- Transwell Migration and Invasion Assays: To quantify the ability of cells to migrate and invade through a matrix.
- Immunofluorescence (IF): To visualize protein localization and interactions within cells.
- Co-Immunoprecipitation (Co-IP): To confirm direct physical interaction between SPOCK1 and SIX1.
- In Vivo Assays:
- Mouse Xenograft Models: Tumors were generated in nude mice by injecting BC cells with modified SPOCK1 expression to assess tumor growth and metastasis.
- Lung Metastasis Models: Cells were injected into the tail vein of mice to evaluate the metastatic potential.
Datasets
The study utilized publicly available datasets for analysis:
- Oncomine: For comparative analysis of SPOCK1 and SIX1 mRNA expression in various cancer types and normal tissues.
- UALCAN: For analyzing SPOCK1 and SIX1 expression in TCGA tumor data and correlating it with clinical parameters.
- Human Protein Atlas (HPA): For protein expression data of SPOCK1 and SIX1.
- TCGA (The Cancer Genome Atlas): For large-scale genomic and clinical data analysis.
- GEPIA2: For analyzing gene expression correlations.
- Kaplan-Meier plotter: For survival analysis (Overall Survival, Relapse-Free Survival, Distant Metastasis-Free Survival, Post-Progression Survival).
- SurvExpress: For risk assessment based on gene expression.
- UCSC Cancer Genomics Browser: For analyzing TCGA data, specifically heat maps of SPOCK1 and EMT markers.
No new datasets were introduced in this paper.
Key Insights and Ideas
- SPOCK1 as a Driver of BC Progression: The study strongly implicates SPOCK1 as a key player in promoting breast cancer growth and metastasis, not just a passive marker.
- The SPOCK1-SIX1 Axis: The discovery of a direct interaction between SPOCK1 and SIX1 is a crucial finding, suggesting a cooperative mechanism in driving cancer progression.
- AKT/mTOR Pathway as the Mediator: The research clearly demonstrates that the SPOCK1-SIX1 interaction activates the AKT/mTOR pathway, which in turn drives downstream effects like cell proliferation and EMT. This provides a specific molecular mechanism.
- EMT as a Key Mechanism: The study highlights the role of SPOCK1 in inducing EMT, a critical step for cancer cells to detach, invade, and metastasize.
- Therapeutic Potential: The identification of SPOCK1 and SIX1 as key drivers, and the AKT/mTOR pathway as a mediator, opens avenues for developing targeted therapies against breast cancer metastasis.
Key Results
- SPOCK1 Overexpression: SPOCK1 was found to be significantly overexpressed in BC tissues compared to normal tissues across multiple databases and IHC analysis.
- Correlation with Poor Prognosis: High SPOCK1 expression was positively associated with higher histological grade, lymph node metastasis, and poorer patient survival (OS, RFS, PPS, DMFS).
- SPOCK1 Promotes Proliferation and Metastasis: In vitro and in vivo experiments showed that SPOCK1 overexpression enhanced BC cell proliferation, colony formation, migration, and invasion, while SPOCK1 knockdown had the opposite effect.
- SIX1 Interaction: SPOCK1 physically interacts with SIX1, and this interaction is crucial for SPOCK1's pro-tumorigenic effects. SIX1 itself is also highly expressed in BC and linked to poor outcomes.
- AKT/mTOR Activation: SPOCK1 and SIX1 co-operatively activate the AKT/mTOR signaling pathway, leading to increased phosphorylation of downstream targets like p-AKT, p-mTOR, p-S6, and p-4EBP1.
- EMT Induction: SPOCK1/SIX1 promotes EMT by upregulating mesenchymal markers (Vimentin, Snail, Slug, Twist, S100A4, ZEB1) and downregulating epithelial markers (E-cadherin, ZO-1).
- Inhibition Reverses Effects: Inhibiting the AKT/mTOR pathway with LY 290042 or Rapamycin reversed the pro-proliferative, pro-metastatic, and EMT-inducing effects of SPOCK1 overexpression. Similarly, SIX1 knockdown also reversed these effects.
Limitations and Future Work
- Further Mechanistic Studies: While the study elucidates the SPOCK1/SIX1/AKT/mTOR axis, the authors acknowledge that "a large of normative studies are still needed to clear this molecular mechanism." This suggests further research is required to fully understand the intricate details of this pathway.
- Clinical Translation: The findings point to SPOCK1 and SIX1 as promising therapeutic targets, but further preclinical and clinical studies would be necessary to translate these findings into effective treatments for BC patients.
- Broader Impact: The authors suggest that their research will "greatly apply novel targets and new treatment strategies for clinicians, leading to broader biomedical impacts," implying a future direction towards clinical application.
Summary updated